Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Clin Endocrinol (Oxf) ; 96(3): 288-301, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34750858

RESUMEN

Obesity is becoming increasingly prevalent in paediatric populations worldwide. In addition to increasing prevalence, the severity of obesity is also continuing to rise. Taken together, these findings demonstrate a worrying trend and highlight one of the most significant challenges to public health. Childhood obesity affects multiple organs in the body and is associated with both significant morbidity and ultimately premature mortality. The prevalence of complications associated with obesity, including dyslipidaemia, hypertension, fatty liver disease and psychosocial complications are becoming increasingly prevalent within the paediatric populations. Treatment guidelines currently focus on intervention with lifestyle and behavioural modifications, with pharmacotherapy and surgery reserved for patients who are refractory to such treatment. Research into adult obesity has established pharmacological novel therapies, which have been approved and established in clinical practice; however, the research and implementation of such therapies in paediatric populations have been lagging behind. Despite the relative lack of widespread research in comparison to the adult population, newer therapies are being trialled, which should allow a greater availability of treatment options for childhood obesity in the future. This review summarizes the current evidence for the management of obesity in terms of medical and surgical options. Both future therapeutic agents and those which cause weight loss but have an alternative indication are also included and discussed as part of the review. The review summarizes the most recent research for each intervention and demonstrates the potential efficacy and limitations of each treatment option.


Asunto(s)
Obesidad Infantil , Adulto , Niño , Humanos , Estilo de Vida , Anamnesis , Obesidad Infantil/terapia , Pérdida de Peso
2.
Horm Res Paediatr ; 96(3): 341-348, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36279852

RESUMEN

INTRODUCTION: McCune-Albright syndrome is characterized by the triad of fibrous dysplasia, café au lait skin pigmentation, and hyperfunctioning endocrinopathies. It is a sporadic condition caused by a missense mutation in the GNAS locus, located on chromosome 20q13.3, resulting in mosaic activation of the G protein alpha subunit. CASE PRESENTATION: We pre­sent a paediatric patient diagnosed with McCune-Albright syndrome at the age of 5 years. During the course of his condition, he was medically managed for a number of complications, such as peripheral precocious puberty and growth hormone excess, and monitored for hyperprolactinaemia. Due to fibroblast growth factor 23-mediated phosphate wasting, the patient was commenced on oral phosphate supplements and alfacalcidol. After 2 years of treatment, this therapy did not optimize his bone biochemistry (phosphate 0.96 mmol/L, alkaline phosphatase 1,172 IU/L, and parathyroid hormone 9.1 pmol/L), and the patient was started on two-weekly burosumab therapy via subcutaneous injection. His bone biochemistry soon normalized (phosphate 1.52 mmol/L, alkaline phosphatase 358 IU/L, and parathyroid hormone 6.9 pmol/L) following this, and he remains on burosumab without any adverse effects. DISCUSSION: This case shows the positive effect that a short-term course of burosumab has on bone health in a paediatric patient with McCune-Albright syndrome. Further research is required to assess long-term effects. Our patient also presented with precocious puberty and growth hormone excess, a coexistence that can be challenging to diagnose and is less common in males. He received medical management for both conditions, but due to the similar presentations, this case highlights the importance to investigate and diagnose associated complications as early as possible, so they can be managed in a timely manner.


Asunto(s)
Displasia Fibrosa Poliostótica , Pubertad Precoz , Masculino , Niño , Humanos , Preescolar , Pubertad Precoz/genética , Displasia Fibrosa Poliostótica/complicaciones , Fosfatasa Alcalina
3.
J Pediatr Endocrinol Metab ; 34(5): 613-618, 2021 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-33823101

RESUMEN

OBJECTIVES: Childhood obesity is a public health concern worldwide, with rates continuing to rise, despite preventive measures. Lifestyle modification remains the mainstay in the treatment of patients with excessive weight, but unfortunately, this is not always successful. Options for medical management of obesity in the paediatric population are limited. METHODS: Seven adolescents (all girls, mean age 14.9 years) with a body mass index (BMI) above 98th percentile and serious complications secondary to obesity were offered an intense weight management programme. The participants were reviewed by a multidisciplinary team every two weeks for advice and support, and treated with daily subcutaneous injections of liraglutide (dose range 1.2-3.0 mg). Scores for anxiety and depression were evaluated using the Revised Child Anxiety and Depression Scale. RESULTS: The results showed a significant weight loss over the three months with an average reduction of 5.4 kg (4.2%; 95% CI 1.93-8.78; p=0.0087). The mean drop in BMI was 2.1 kg/m2, which is statistically significant (95% CI 0.973-3.199; p=0.0037). Resolution of complications (raised intracranial pressure and steatohepatitis) was noted following weight loss. Anxiety and depressive symptoms improved over the three-month intervention course, especially features of separation anxiety disorder. Liraglutide was well tolerated by all patients. CONCLUSIONS: Liraglutide medication, alongside a dedicated multidisciplinary team guided lifestyle therapy, is effective and safe in the treatment for excessive weight in adolescents, leading to the reversal of the complications related to obesity and improvement in the psychological symptoms.


Asunto(s)
Terapia Conductista/métodos , Ejercicio Físico , Hipoglucemiantes/uso terapéutico , Estilo de Vida , Liraglutida/uso terapéutico , Obesidad Infantil/terapia , Adolescente , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Pronóstico
4.
J Pediatr Adolesc Gynecol ; 33(4): 339-342, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32035994

RESUMEN

STUDY OBJECTIVE: Puberty is a normal process for adolescents, and the first signs may include change in body odor, breast development, or pubic hair growth. This is then followed by menarche approximately 2 years later. Vaginal bleeding in pre-pubertal female individuals is rare. The aim of this study was to investigate causes of pre-pubertal bleeding in a group of patients. DESIGN, SETTING, METHOD, AND MAIN OUTCOME MEASURES: Seventeen patients who presented with pre-pubertal recurrent vaginal bleeding with no other signs of precocious puberty were investigated, to determine the cause of this symptom. RESULTS: The mean age for the onset of vaginal bleeding was 7.4 years, ranging from 4 to 9.67 years. Gonadotrophin-releasing hormone (GnRH) stimulation tests showed a pre-pubertal response in all cases. Pelvic ultrasound scans showed a pre-pubertal uterus in all patients. Two patients were found to have foreign bodies identified during a genital examination under anesthetic, and in both cases removal of the foreign bodies terminated the vaginal bleeding. CONCLUSION: In conclusion, recurrent vaginal bleeding was not associated with GnRH response, raised estradiol levels, or abnormal pelvic ultrasound findings. In cases of recurrent vaginal bleeding with normal hormonal investigations in pre-pubertal girls, it is recommended that a genital examination under anesthetic be undertaken to rule out undiagnosed causes of the presenting symptom.


Asunto(s)
Pubertad Precoz/etiología , Hemorragia Uterina/etiología , Niño , Preescolar , Femenino , Hormona Liberadora de Gonadotropina/análisis , Examen Ginecologíco/métodos , Humanos , Pubertad/fisiología , Ultrasonografía , Hemorragia Uterina/diagnóstico
5.
Diabetes Metab Syndr ; 13(1): 492-495, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30641751

RESUMEN

INTRODUCTION: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder that interferes with the function of the beta cells in the pancreas. Reports show that the incidence of T1DM is increasing throughout England and Wales, along with the Body Mass Index (BMI) of this patient group. The association between type 2 diabetes mellitus (T2DM) and obesity is recognised, but literature describing the association between T1DM and high BMI is more limited. The aim of this paper is to identify factors affecting BMI and the impact that this increasing trend has on children and young people with T1DM. METHODS: Information was obtained from the medical records of patients with T1DM at the local paediatric centre. BMI standard deviation scores (SDS) were calculated and compared to other factors, which include insulin requirement, HbA1c, pubertal status and age at diagnosis. RESULTS: This study involved 102 patients (43 male and 59 female). The mean age at diagnosis was 7.79 years (range from 0.16 to 16.91 years). Our results showed a significant association between insulin requirement and BMI SDS (r = 0.23, p = 0.02) and a significant association between insulin requirement and mean HbA1c (r = 0.59, p=<0.01). A multivariable regression analysis of factors affecting BMI SDS showed that insulin requirement was an independent factor affecting BMI SDS. CONCLUSION: There were significant associations between increased insulin requirement, high BMI SDS and poorer glycaemic control. Further research is required to fully understand the risk factors that may contribute to obesity in T1DM.


Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Hipoglucemiantes/metabolismo , Resistencia a la Insulina , Insulina/metabolismo , Obesidad Infantil/etiología , Adolescente , Biomarcadores/análisis , Índice de Masa Corporal , Niño , Preescolar , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Femenino , Estudios de Seguimiento , Humanos , Hipoglucemiantes/administración & dosificación , Lactante , Insulina/administración & dosificación , Masculino , Obesidad Infantil/patología , Pronóstico
7.
Rev Diabet Stud ; 14(2-3): 295-300, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29145539

RESUMEN

BACKGROUND: Socioeconomic deprivation, obesity, and emotional discomfort are important determinants of health inequalities and poor glycemic control in children and young people with type 1 diabetes mellitus (T1D). OBJECTIVES: The aims of this study were to evaluate the incidence of hospital admissions of T1D children in relation to socioeconomic deprivation, and to determine the effects of social deprivation, body mass index (BMI), and patient-reported emotional well-being on glycemic control. METHODS: All hospital admissions of T1D patients aged 1-18 years were identified during 2007 and 2012. Admission cause and glycemic control were related to social deprivation, BMI, and psychological, emotional well-being. Indices of Multiple Deprivation (IMD) 2010 were applied to the United Kingdom data. The associations were calculated using the Spearman's rank correlation coefficient. RESULTS: A significant correlation was found between hospital admission rates and overall deprivation scores (r = -0.18, p = 0.04). Patients living in deprived areas were more likely to selfpresent to the accident and emergency department (r = -0.24, p = 0.02). Poor glycemic control (n = 124) was significantly associated with lower levels of education (r = -0.22, p = 0.02) and unemployment (r = -0.19, p = 0.04). Significance was not reached for level of income (r = -0.16, p = 0.07) and overall deprivation (r = -0.17, p = 0.06). Glycemic control was not found to be associated with BMI, standard deviation scores (SDS), or emotional well-being. CONCLUSION: Early intervention and education from primary care and specialist diabetes teams within the community in deprived areas may be effective in reducing hospital admissions for diabetes-related problems and improving glycemic control.


Asunto(s)
Diabetes Mellitus Tipo 1/epidemiología , Empleo , Hospitalización/estadística & datos numéricos , Factores Socioeconómicos , Adolescente , Glucemia , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA